Altis Labs, whose AI model analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, has raised a $25M Series A (Natalie Breymeyer/Axios)
Altis has new capital for software meant to read oncology-trial CT scans as survival signals.
The company raised a $25 million Series A, CEO Felix Baldauf-Lenschen told Axios Pro. Its model analyzes CT scans from cancer drug trials and produces predictions tied to patient survival. Techmeme’s item describes Altis as an AI software company for drug development, but gives no further terms or investor details. Techmeme's note
The company raised a $25 million Series A, CEO Felix Baldauf-Lenschen told Axios Pro. Its model analyzes CT scans from cancer drug trials and produces predictions tied to patient survival. Techmeme’s item describes Altis as an AI software company for drug development, but gives no further terms or investor details. Techmeme's note
score 6